marketing exhibits st louis cardinals memorabilia rights to cardinals baseball tickets tells that medicine.Ista shares jumped as much as 30 percent after the positive recommendation for its Bepreve eye drops, hitting a 17-month high of $5.53 before giving back most of the gains.The panel of Food and Drug Administration advisers voted 7-0 that Ista had adequately demonstrated the safety and effectiveness of Bepreve, which would be sold by prescription if the agency granted final approval.Studies by Ista "all deliver the same message and that's in support of safety and effectiveness," said panel member Philip Lavin, executive chairman of Averion International Corp, a clinical research organization.The FDA usually approves drugs recommended by advisory panels, which are groups of outside doctors and other scientific experts. A final decision on Bepreve is due by September 12, although the FDA has missed several target dates over the past year.SunTrust Robinson Humphrey analyst Frank Pinkerton has forecast Bepreve sales of $12 million in 2010 if the drug won approval for U.S. sales.Ista's net revenue for 2008 was $83 million with a net loss of nearly $31 million. The company sells the eye drugs Xibrom, Vitrase and Istalol and predicts its operating income will roughly break even in 2009.Several medicines are approved for treating allergies, but Ista said there was a need for new options with fewer side effects. Approved drugs may cause sleepiness, dry mouth and other problems.The most frequent side effect seen in studies of Bepreve was changes in taste, such as a bitter taste or aftertaste reported by 25 percent of patients treated with the drug in one study. The drug is widely sold in other countries, the company said.Collins Stewart analyst Louise Chen, in a research note, said expectations for Rejena were "modest" and the panel decision "does not change our view that (Alcon) is a global leader in ophthalmology, and a high quality company with good long-term growth prospects." She has a "buy" rating on the stock.Ista shares were halted during the panel meeting. When trading resumed after the decision, the stock rose as high as $5.53 before ending up 43 cents, or 10.14 percent, at $4.67 on Nasdaq.Alcon rose 0.62 percent to $116.44 on the New York Stock Exchange.(Reporting by Lisa Richwine; editing by Gerald E McCormick, Lisa Von Ahn and Richard Chang) Asian Markets.
NEW YORK (Reuters) - Auto parts maker Lear Corp (LEA.N), which has been weighed down by heavy debt and a sharp decline in automobile demand, is expected to file for bankruptcy by June 30, sources close to the deal told Reuters Loan Pricing Corp.The move comes after Lear, which has been in talks with lenders, warned in March it might have to file for bankruptcy and as some of its automaker customers struggle with bankruptcy themselves.The filing would come around the time a waiver from lenders on its loan defaults expires on June 30 st louis cardinals . It breached its leverage covenants at the end of 2008 after borrowing all of the $1.2 billion in its main credit facility.Sources also told RLPC that Lear is set to secure $500 million in bankruptcy financing, or a "debtor-in-possession" loan, that would be led by JP Morgan (JPM.N).Lear is also near the end of a 30-day grace period on a $38 million interest payment on certain bonds it missed on June 1 stl cardinals . Missing the payment was part of its waiver agreement on the credit facility.Lear, which makes seating and electrical equipment for vehicles, declined to comment.The company has suffered because of steep production cuts by General Motors Corp GMGMQ.PK and Ford Motor Co (F.N) st louis cardinals photo . Auto parts makers were also pressured after Chrysler shut down nearly all of its production as part of its bankruptcy reorganization.Most of Chrysler is now out of bankruptcy and is being operated by Fiat SpA (FIA.MI) It plans to restart production on Monday st louis cardinals shop .
GM is currently in bankruptcy and idled 13 assembly plants in North America for as long as nine weeks starting in mid-May.The Obama administration, which made $5 billion available to guarantee receivables GM and Chrysler owed suppliers earlier this year, rejected a new request by suppliers for up to $10 billion in additional loans this month.Suppliers have warned the lack of new aid would result in a number of bankruptcies because the companies lack capital to ramp up production in the third quarter to meet expected demand from Chrysler and GM.RLPC is Thomson Reuters (TRI.TO) company.(Reporting by Caroline Humer; additional reporting by Soyoung Kim in Detroit and Thomas Hals and Phil Wahba in New York; editing by Lisa Von Ahn, Andre Grenon, Tim Dobbyn) st louis cardinals sweatshirt . * FDA advisers vote 7-0 in favor of Bepreve Stocks | Regulatory News * Agency usually approves drugs with panel backing * Ista shares jump as much as 30 percent * Panel rejects River Plate, Alcon dry eye drug (Adds analyst comment) By Lisa Richwine SILVER SPRING, Md., June 26 (Reuters) - Ophthalmic drugmaker Ista Pharmaceuticals Inc (ISTA.O) won unanimous supportfrom a U.S st louis cardinals dvd . advisory panel on Friday for new drops to treatitchiness in the eye caused by allergies st louis cardinals throw . The committee rejected a second drug developed by privatelyheld River Plate Biotechnology for treating dry eye Alcon Inc(ACL.N) holds U.S marketing rights to that medicine st louis cardinals watch . Ista shares jumped as much as 30 percent after the positiverecommendation for its Bepreve eye drops, hitting a 17-monthhigh of $5.53 before giving back most of the gains. The panel of Food and Drug Administration advisers voted7-0 that Ista had adequately demonstrated the safety andeffectiveness of Bepreve, which would be sold by prescriptionif the agency granted final approval.
Studies by Ista "all deliver the same message and that's insupport of safety and effectiveness," said panel member PhilipLavin, executive chairman of Averion International Corp, aclinical research organization st louis cardinals caps . The FDA usually approves drugs recommended by advisorypanels, which are groups of outside doctors and otherscientific experts st louis cardinals lamp . A final decision on Bepreve is due by Sept.12, although the FDA has missed several target dates over thepast year cardinals baseball tickets . SunTrust Robinson Humphrey analyst Frank Pinkerton hasforecast Bepreve sales of $12 million in 2010 if the drug wonapproval for U.S sales stl cardinals . Ista's net revenue for 2008 was $83 million with a net lossof nearly $31 million.
The company sells the eye drugs Xibrom,Vitrase and Istalol and predicts its operating income willroughly break even in 2009 st louis cardinals sweatshirts . Several medicines are approved for treating allergies, butIsta said there was a need for new options with fewer sideeffects st louis cardinals photo . Approved drugs may cause sleepiness, dry mouth andother problems st louis cardinals shop . The most frequent side effect seen in studies of Beprevewas changes in taste, such as a bitter taste or aftertastereported by 25 percent of patients treated with the drug in onestudy . Ista officials said cases were mild and transient andthe drug was safe in people as young as 3.
Comments are closed.